AstraZeneca (AZN.L) stock price, revenue, and financials

AstraZeneca market cap is £162.9 b, and annual revenue was $37.42 b in FY 2021

£162.9 B

AZN.L Mkt cap, 27-Apr-2022

$37.4 B

AstraZeneca Revenue FY, 2021
AstraZeneca Gross profit (FY, 2021)33 B
AstraZeneca Net income (FY, 2021)115 M
AstraZeneca EBITDA (FY, 2021)7 B
AstraZeneca EBIT (FY, 2021)992 M
AstraZeneca Cash, 31-Dec-20216.3 B
AstraZeneca EV187.3 B
Get notified regarding key financial metrics and revenue changes at AstraZenecaLearn more
Banner background

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 34.9% from ONCOLOGY, 6.3% from OTHER MEDICINES, 10.7% from COVID-19, 21.4% from BIOPHARMACEUTICALS: CVRM, 16.1% from BIOPHARMACEUTICALS: R&I, 8.2% from RARE DISEASE and 2.3% from Other

AstraZeneca Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

22.1b24.4b26.6b37.4b

Cost of goods sold

(1.2b)(1.2b)(2.2b)(5.9b)

Gross profit

21.7b23.7b25.0b33.0b

R&D expense

(5.9b)(6.1b)(6.0b)(9.7b)

Operating expense total

(16.4b)(18.2b)(17.8b)(25.9b)

Depreciation and amortization

(3.8b)(3.8b)(3.1b)(6.5b)

EBITDA

5.2b5.4b7.2b7.0b

EBIT

3.3b2.8b5.1b992.0m

Interest expense

(1.4b)(1.4b)(1.3b)(1.3b)

Interest income

138.0m22.0m36.0m

Pre tax profit

2.0b1.5b3.9b(265.0m)

Income tax expense

57.0m(321.0m)(772.0m)380.0m

Net Income

2.1b1.2b3.1b115.0m

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

5.5b5.8b6.4b6.4b6.3b6.6b7.3b8.2b9.9b

Cost of goods sold

(453.0m)(336.0m)(635.0m)(579.0m)(274.0m)(569.0m)(1.1b)(1.4b)(969.0m)

Gross profit

5.6b5.6b6.1b6.3b6.1b6.3b7.4b6.9b8.9b

R&D expense

(1.3b)(1.4b)(1.3b)(1.4b)(1.4b)(1.5b)(1.7b)(1.8b)(3.6b)

Operating expense total

(4.4b)(3.9b)(4.6b)(4.6b)(3.8b)(4.9b)(5.1b)(4.7b)(8.2b)

Depreciation and amortization

(676.0m)(727.0m)(716.0m)(841.0m)(710.0m)(801.0m)(797.0m)(753.0m)(2.8b)

EBITDA

1.2b1.7b1.4b1.7b2.3b1.4b2.4b2.1b736.0m

EBIT

1.1b461.0m725.0m1.2b1.3b1.2b1.9b1.1b(1.7b)

Interest expense

(367.0m)(361.0m)(353.0m)(332.0m)(329.0m)(324.0m)(303.0m)(326.0m)(335.0m)

Interest income

55.0m41.0m37.0m51.0m22.0m7.0m20.0m7.0m15.0m

Pre tax profit

758.0m141.0m409.0m935.0m961.0m853.0m1.6b764.0m(2.0b)

Income tax expense

(195.0m)(34.0m)(129.0m)(185.0m)(223.0m)(202.0m)(46.0m)(214.0m)350.0m

Net Income

563.0m107.0m280.0m750.0m738.0m651.0m1.6b550.0m(1.7b)

AstraZeneca Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

4.8b5.4b7.8b6.3b

Accounts Receivable

3.0b3.6b3.8b9.6b

Prepaid Expenses

1.6b1.2b2.1b663.0m

Inventories

2.9b3.2b4.0b9.0b

Current Assets

15.6b15.6b19.5b26.2b

PP&E

7.4b8.3b8.3b9.2b

Goodwill

11.7b11.7b11.8b20.0b

Total Assets

60.7b61.4b66.7b105.4b

Accounts Payable

1.7b1.8b2.4b18.9b

Short-term debt

1.8b2.0b2.3b1.9b

Current Liabilities

16.3b18.1b20.3b22.6b

Long-term debt

17.4b16.2b18.0b28.9b

Non-Current Liabilities

30.3b28.7b30.8b43.5b

Total Debt

19.1b18.2b20.3b30.8b

Total Liabilities

46.6b46.8b51.1b66.1b

Common Stock

317.0m328.0m328.0m387.0m

Additional Paid-in Capital

4.4b7.9b8.0b35.1b

Retained Earnings

5.7b2.8b5.3b1.7b

Total Equity

14.0b14.6b15.6b39.3b

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

4.1b5.4b4.0b3.4b5.7b8.1b7.6b15.6b7.1b

Accounts Receivable

5.3b5.3b5.3b5.1b5.0b5.7b6.3b6.4b8.3b

Prepaid Expenses

118.0m246.0m228.0m262.0m213.0m332.0m347.0m486.0m596.0m

Inventories

3.1b3.2b3.1b3.1b3.6b3.7b4.3b4.8b10.5b

Current Assets

13.6b15.2b13.5b12.8b14.9b18.2b18.7b27.3b26.7b

PP&E

7.4b7.4b8.0b7.3b7.5b7.7b8.2b8.4b9.2b

Goodwill

11.7b11.7b11.6b11.6b11.6b11.7b11.8b11.8b20.1b

Total Assets

61.1b61.9b58.9b57.2b59.9b64.1b64.9b73.6b107.2b

Accounts Payable

13.1b12.6b12.5b12.6b12.0b13.4b17.4b17.7b18.7b

Short-term debt

3.7b1.8b577.0m2.5b4.1b3.6b2.3b2.9b3.0b

Current Liabilities

18.3b16.0b14.8b17.0b18.2b18.9b21.5b22.2b23.6b

Long-term debt

17.9b17.9b17.6b16.1b15.6b18.8b17.9b24.6b28.9b

Non-Current Liabilities

30.8b30.8b30.5b28.0b28.1b31.6b29.0b35.7b43.7b

Total Debt

21.6b19.7b18.2b18.6b19.7b22.3b20.1b27.5b31.9b

Total Liabilities

49.0b46.8b45.2b45.0b46.3b50.5b50.5b57.9b67.3b

Common Stock

317.0m328.0m328.0m328.0m328.0m328.0m328.0m328.0m387.0m

Additional Paid-in Capital

4.4b7.9b7.9b7.9b8.0b8.0b8.0b8.0b35.1b

Retained Earnings

3.7b3.3b1.9b448.0m1.9b1.9b4.1b5.3b2.2b

Total Equity

12.0b15.1b13.7b12.2b13.7b13.6b14.4b15.7b39.9b

AstraZeneca Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

2.0b1.5b3.9b(265.0m)

Depreciation and Amortization

3.8b3.8b3.1b6.5b

Accounts Receivable

(523.0m)(898.0m)(739.0m)

Inventories

(13.0m)(316.0m)(621.0m)

Accounts Payable

(103.0m)868.0m1.7b

Cash From Operating Activities

2.6b3.0b4.8b6.0b

Cash From Investing Activities

963.0m(657.0m)(285.0m)(11.1b)

Short-term Borrowings

(98.0m)(516.0m)288.0m(516.0m)

Long-term Borrowings

1.6b(1.0b)1.4b8.2b

Dividends Paid

(3.5b)(3.6b)(3.6b)(3.9b)

Cash From Financing Activities

(2.0b)(1.8b)(2.2b)3.6b

Net Change in Cash

1.5b552.0m2.3b(1.5b)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

758.0m899.0m1.3b935.0m1.9b2.7b1.6b2.4b371.0m

Depreciation and Amortization

676.0m1.4b2.1b841.0m1.6b2.4b797.0m1.6b4.3b

Cash From Operating Activities

(387.0m)491.0m1.6b139.0m1.2b3.0b1.9b2.8b4.5b

Cash From Investing Activities

328.0m(789.0m)(715.0m)9.0m157.0m(423.0m)555.0m319.0m(10.1b)

Short-term Borrowings

1.2b(148.0m)(686.0m)123.0m1.4b858.0m(240.0m)(182.0m)(261.0m)

Long-term Borrowings

500.0m(1.0b)3.0b(4.0m)7.3b9.0b

Dividends Paid

(2.4b)(2.4b)(3.6b)(2.4b)(2.5b)(3.7b)(2.5b)(2.5b)(3.9b)

Cash From Financing Activities

(698.0m)941.0m(1.8b)(2.4b)(1.2b)7.0m(2.7b)4.6b4.7b

Net Change in Cash

(745.0m)659.0m(892.0m)(2.2b)82.0m2.6b(309.0m)7.7b(973.0m)

AstraZeneca Ratios

USDFY, 2018

EV/EBITDA

21.5 x

EV/EBIT

33.8 x

EV/CFO

42.2 x

Revenue/Employee

342.0k

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020Q4, 2020FY, 2020

Projects in R&D Pipeline

99133146132144149167171

Phase I Trials Projects

3324444150383435

Phase II Trials Projects

2711333637435042

Phase III Trials Projects

1911352723222725

Life-cycle Management Projects

34465669

Blood Pressure Screenings (Africa)

5.7 m9.97 m13.5 m16.7 m

New Phase I Projects

5343111553355

New Phase II Projects

23412145514388

New Pivotal Study Projects

215666315688

New Projects to Registration

3131551322

NME Phase I (Oncology)

21191817262621212018182019202121

NME Phase II (Oncology)

341010202025222527272524252121

NME in Late-stage Development (Oncology)

54441111141714121279101010

NME Phase I (Biopharmaceuticals)

13121213131313131416161716171414

NME Phase II (Biopharmaceuticals)

18171717232322222122222021212121

NME in Late-stage Development (Biopharmaceuticals)

4432333355546555

Healthcare Workers Trained

10.82 k35.89 k81.61 k132.25 k

People Reached (Healthcare Programmes)

7.17 m12.01 m16.42 m25.03 m

People Reached (Patient Assistance Programmes)

9 m9.3 m9.7 m10.1 m

NME Phase I

34263227

NME Phase II

20253936

NME in Late-stage Development

118810

Countries

100100100100

Health Facilities Activated

8272 k2.62 k3.36 k

Patients Included in Clinical Trials

33 k

Scientific Collaborations

600630730800

Young Health Programme Members

2.25 m3.01 m4.01 m

AstraZeneca Human Capital

FY, 2019FY, 2018FY, 2017
Male, percent10%10%10%
Male (Senior and Middle Management), percent10.9%11.1%11.1%
Female (Senior and Middle Management), percent9.1%8.9%8.9%
Female (Management), percent8.3%8.3%8.1%
Female (Executive Leadership), percent6.4%6%5.6%
Male (Executive Leadership), percent13.6%14%14.4%
Female (Board), percent6.7%8.4%8.4%
Male (Board), percent13.3%11.6%11.6%
Male (Management), percent11.7%11.7%11.9%
Female, percent10%10%10%

AstraZeneca Employee Rating

4.15425 votes
Culture & Values
4.1
Work/Life Balance
3.9
Senior Management
3.7
Salary & Benefits
4.1
Career Opportunities
3.8
Source